



Testosterone therapy: An assessment of the clinical consequences of changes in haematocrit and blood flow characteristics

Journal:	<i>Sexual Medicine Reviews</i>
Manuscript ID	SMR-11-2018-070.R2
Article type:	Review
Keywords:	Late onset testosterone deficiency, Testosterone therapy, Haematocrit, Type 2 Diabetes, blood viscosity, microvascular flow
Subject Area:	Risk factors/co-morbidities < BASIC SCIENCE < MALE, Sex steroid replacement < TREATMENT < MALE
Abstract:	<p>Introduction. Clinical guidelines indicate that haematocrit should be monitored during testosterone replacement therapy (TTh) with action taken if a level of 0.54 is exceeded.</p> <p>Aim. To consider the extent of changes in haematocrit and putative effects on viscosity, blood flow and mortality following TTh.</p> <p>Methods. We focused on literature describing benefits and possible pitfalls of TTh including increased haematocrit. We used data from the BLAST RCT to determine change in haematocrit after 30 weeks of TTh and describe a clinical case showing the need for monitoring. We consider the validity of the current haematocrit cut-off value at which TTh may be modified. Ways in which haematocrit alters blood flow in the micro- and macro-vasculature are also considered.</p> <p>Main Outcome Measures. (1) change in haematocrit, (2) corresponding actions taken in clinical practice and (3) possible blood flow changes following change in haematocrit.</p> <p>Results. Analysis of data from the BLAST RCT showed a significant increase in mean haematocrit of 0.01, the increase greater in men with lower baseline values. While, none of 61 men given TTh breached the suggested cut-off of 0.54 after 30 weeks, a clinical case demonstrates the need to monitor haematocrit. An association between haematocrit and morbidity and mortality appears likely but not proven and, may be evident only in patient subgroups. The consequences of an increased haematocrit may be mediated by alterations in blood viscosity, oxygen delivery and flow. Their relative impact may vary in different vascular beds.</p> <p>Conclusions. TTh can effect an increased haematocrit via poorly understood mechanisms and may have harmful effects on blood flow that differ in patient subgroups. At present, there appears no scientific basis for using an haematocrit of 0.54 to modify TTh; other values may be more appropriate in particular patient groups.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Abstract.**
4

5
6 **Introduction.** Clinical guidelines indicate that haematocrit should be monitored
7
8 during testosterone replacement therapy (TTh) with action taken if a level of 0.54 is
9
10 exceeded.
11

12
13 **Aim.** To consider the extent of changes in haematocrit and putative effects on
14
15 viscosity, blood flow and mortality following TTh.
16

17
18 **Methods.** We focused on literature describing benefits and possible pitfalls of TTh
19
20 including increased haematocrit. We used data from the BLAST RCT to determine
21
22 change in haematocrit after 30 weeks of TTh and describe a clinical case showing
23
24 the need for monitoring. We consider the validity of the current haematocrit cut-off
25
26 value at which TTh may be modified. Ways in which haematocrit alters blood flow in
27
28 the micro- and macro-vasculature are also considered.
29

30
31 **Main Outcome Measures.** (1) change in haematocrit, (2) corresponding actions
32
33 taken in clinical practice and (3) possible blood flow changes following change in
34
35 haematocrit.
36

37
38 **Results.** Analysis of data from the BLAST RCT showed a significant increase in
39
40 mean haematocrit of 0.01, the increase greater in men with lower baseline values.
41
42 While, none of 61 men given TTh breached the suggested cut-off of 0.54 after 30
43
44 weeks, a clinical case demonstrates the need to monitor haematocrit. An association
45
46 between haematocrit and morbidity and mortality appears likely but not proven and
47
48 may be evident only in patient subgroups. The consequences of an increased
49
50 haematocrit may be mediated by alterations in blood viscosity, oxygen delivery and
51
52 flow. Their relative impact may vary in different vascular beds.
53
54

55
56 **Conclusions.** TTh can effect an increased haematocrit via poorly understood
57
58 mechanisms and may have harmful effects on blood flow that differ in patient
59
60

1
2
3 subgroups. At present, there appears no scientific basis for using a haematocrit of
4
5 0.54 to modify TTh; other values may be more appropriate in particular patient
6
7 groups.
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Introduction

Use of testosterone therapy (TTh) is increasing rapidly worldwide. For example, in the United States the cost of TTh in 2013 was \$2.4 billion with an expected increase to \$3.8 billion in 2018 (<https://www.statista.com/statistics/320301/predicted-annual-testosterone-drug-revenues-in-the-us/> - accessed on 01/11/2018). Though the benefits of TTh in terms of reduced risk of cardiovascular disease (CVD) and mortality are reported in an increasing number of studies, some reports present a contrary view. This review is in two sections; the first considers the merits of TTh in men with low serum testosterone and associations between increased haematocrit, a well recognised adverse effect of the therapy, and morbidity / mortality. The second part considers the association between haematocrit and blood flow and discusses putative mechanisms whereby TTh may lead to development of pathology. Our approach has been to review the literature and present unpublished data from our BLAST randomised controlled trial that describes the relationship between TTh, increased haematocrit, morbidity and mortality. The importance of monitoring haematocrit is emphasised in a case report showing TTh leading to a markedly increased haematocrit requiring phlebotomy and replacement of injectable TTh with a gel formulation. We also speculate on the effect that increased numbers of red cells could have on blood flow characteristics in different vascular beds. The review is based on publications from basic science, longitudinal and randomised controlled trials and reviews known to us or selected from Pubmed (US National Library of Medicine).

Testosterone Deficiency.

Testosterone deficiency (TD), characterised by low testosterone levels and related symptoms, occurs in 6–12% of men [1,2]. TD is associated with decreased bone

1
2
3 mineral density, lean mass, muscle strength, cognitive function, sexual function and
4 increased fat mass [1,2,3]. The phenotype is categorised as primary TD, secondary
5 TD (pituitary/hypothalamic disease) or adult onset TD. Adult onset TD describes in
6 men older than 50 years (following exclusion of hypothalamic-pituitary-testicular axis
7 pathology), a combination of low serum testosterone levels and accompanying
8 symptoms. The condition is associated with obesity, type 2 diabetes (T2DM) and the
9 metabolic syndrome (MetS) [3,4]. Prevalence of adult onset TD in men with T2DM is
10 about 40% [5,6]. Indeed, low testosterone levels are associated with the number and
11 severity of components classifying the metabolic syndrome (increased waist
12 circumference / body mass index, glycaemia, triglycerides, blood pressure and
13 decreased high density lipoprotein cholesterol) and τ may also predict the onset of
14 diabetes in younger men [7].

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Importantly, adult onset TD is associated with increased morbidity and mortality [4].
32 For example, the European Male Ageing study, (2599 men, {7% with T2DM, aged 40-
33 79 years, about 4 years follow-up) showed the combination of TD symptoms and
34 total testosterone <8nmol/l (230.5ng/dl) was significantly associated with increased
35 total and CVD mortality [7]. Importantly, there is also accumulating evidence from
36 longitudinal observational studies that TTh can lead to improved sexual health and
37 reduced all-cause mortality [4]. Shores et al studied the impact of TTh on mortality in
38 1031 males (aged over 40 years, total testosterone \leq 8.7 nmol/l (250.7ng/dl), mean
39 follow-up about 4 years), mortality in 398 men on TTh was 10.3%}, compared with
40 untreated controls (20.7%) [9]. Survival analysis showed significantly reduced
41 mortality in men with T2DM but not in their non-diabetic counterparts. This finding
42 was confirmed by 2 longitudinal studies of men with T2DM. Muraleedaran et al
43 studied over 6 years, the effects of low testosterone (the cohort stratified by total
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 testosterone of 10.4 nmol/l (299.7ng/dl)) and TTh on mortality in 581 men with T2DM
4 [10]. Mortality was higher in 238 men with low testosterone (HR: 2.02, 95% CI: 1.2 -
5 3.4) compared to those with values above 10.4 nmol/l (299.7ng/dl) after adjustment
6 for confounders. In the low testosterone group, the 174 men not on TTh were at
7 significantly higher risk of mortality (HR: 2.3, 95% CI: 1.3 - 3.9) than the 64 men
8 receiving TTh. A longitudinal study in 857 men with T2DM by our group showed
9 similar results [11]. We stratified the cohort using a total testosterone cut-off of 12.0
10 nmol/l (345.8ng/dl) and free testosterone of 0.25 nmol/l (7.2ng/dl); over a mean 3.8
11 years, mortality was reduced in men on TTh with greatest benefit in older men
12 [11,12]. Survival analysis (adjusted for age, phosphodiesterase 5-inhibitor and statin
13 treatment) showed that compared with men with low testosterone (either low total or
14 calculated free testosterone) not on TTh, mortality was lower in men with normal
15 testosterone (HR: 0.62, CI: 0.41 - 0.94) and men with low testosterone on TTh (HR:
16 0.38, CI: 0.16 - 0.90). This benefit was independent of changes in conventional
17 cardiovascular/metabolic risk factors (weight, body mass index, dyslipidaemia,
18 glycaemic control, blood pressure) [13]. Further, Snyder et al. in the Testosterone
19 trial, showed significant benefits in sexual function, mood, depression, quality of life,
20 physical performance, vitality, anaemia and bone mineral density in the overall
21 group, although this benefit was not evident in the individual studies [14]. The BLAST
22 randomised controlled study suggested improvements in erectile dysfunction
23 following TTh, especially in men with total testosterone levels < 8nmol/l; the change
24 reaching statistical significance only after 6 months of therapy [15, 16] with
25 improvement continuing even after 4 years [17].

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57 The above data provides the basis for the British Society for Sexual Medicine [4] and
58 International Society for Sexual Medicine guidelines
59
60

(<https://professionals.issm.info/wp-content/uploads/sites/2/2018/05/ISSM-Quick-Reference-Guide-on-TD.pdf> - accessed on 02/01/2019) that include the following management recommendations;

- Total testosterone <8nmol/l (230.5ng/dl) or free testosterone <0.180nmol/l (5.2ng/dl): usually requires TTh.
- Total testosterone >12nmol/l (345.8ng/dl) or free testosterone >0.225nmol/l (6.5ng/dl) : does not require TTh.
- Total testosterone 8-12nmol/l (230.5-345.8ng/dl) may require a trial of TTh for a minimum of 6 months depending on symptoms.

Possible cardiovascular adverse effects associated with TTh.

Concern continues to exist (<https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm> - accessed on 02/01/2019)

(http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Testosterone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500175213.pdf - accessed on 02/01/2019) regarding the cardiovascular safety of TTh in the treatment of adult onset TD. Thus, while most studies demonstrate either benefit or no increase in cardiovascular events, a few widely cited studies have reported increased CVD in patients on TTh [18,19]. Vigen et al used a composite of all-cause mortality, myocardial infarction and stroke rates as outcome in patients with low testosterone levels who had undergone coronary angiography and subsequently received TTh [20]. Though the event rate was 10.1% in testosterone treated and 21.2% in untreated patients, after adjustment for over 50 variables (baseline testosterone and erectile dysfunction, both associated with all-cause mortality were not included), TTh appeared associated with increased events

1
2
3 (25.7% in treated, 19.9% in untreated groups) during 3 years follow-up. Finkle et al
4 examined 55,593 insurance claims and compared the incidence rate of myocardial
5 infarction in the 12 months prior and 3 months after the initial prescription of TTh and
6 reported an increased rate of non-fatal myocardial infarctions especially in men aged
7 65 years or older [21]. In younger men, the risk was confined to those with pre-
8 existing heart disease. Importantly the control group was comprised of men
9 commenced on phosphodiesterase 5-inhibitors which have been demonstrated to
10 lower cardiovascular and all-cause mortality [11,12,22,23]. Further, there were
11 design flaws including lack of data on testosterone levels, the reporting of only non-
12 fatal events and a retrospective review of the previous 12 months only after the
13 decision on TTh was made. Three months follow up may be insufficient to detect
14 benefit from TTh and the authors conceded that increased events could be related to
15 TD rather than TTh. Basaria et al published the 'Testosterone in Older men with
16 Mobility Limitations (TOM) Trial' of 209 older men (mean age: 74 years) with limited
17 mobility randomised to either testosterone or placebo gel [24]. Though the primary
18 outcome (change in maximal voluntary muscle strength during leg press exercise)
19 was met, the trial was discontinued as 23 men given TTh and 5 men given placebo
20 appeared to develop cardiovascular related adverse events. However, in addition to
21 the limitations imposed by a relative small cohort there was no cardiovascular
22 assessment at baseline and events were based on self reporting and included a
23 wide range of symptoms including peripheral oedema and syncope. Though these
24 studies have flaws and the mechanism for the putative adverse effect of TTh is
25 unidentified, they do indicate a need to better assess potential problems in using TTh
26 especially in patient subgroups.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We recently speculated on the effects that patient heterogeneity could have on
4 treatment benefits [25]. For example, a small patient subgroup may be at an
5 increased risk that cannot be detected in large trials with wide inclusion criteria.
6 Accordingly, clinical outcomes associated with TTh need to be identified using
7 randomised controlled trials and observational longitudinal studies that evaluate
8 benefits and adverse effects in the total cohort and subgroups.
9

17 **Increased haematocrit following TTh**

18
19
20 In this context, the effects of TTh on haematocrit and potentially clinical outcome are
21 important. Thus, an increase in haematocrit is the commonest adverse effect linked
22 with TTh [26, 27, 28] with values >0.54 used to alter dose or discontinue treatment
23 [4].
24
25
26
27
28
29

30 The need for regular monitoring of haematocrit is exemplified in a case report.

31 Patient MM, a male aged 53 years was referred to the metabolic clinic at University
32 Hospitals Birmingham NHS Foundation Trust in 2007 with severe fatigue, erectile
33 dysfunction and the MetS. He was diagnosed with T2DM in 2012 with a total
34 testosterone of 3.6 nmol/l (103.7ng/dl), LH: 0.6IU/l, FSH: 3.6IU/l) and similar values
35 on repeat testing (fasting sample at 9 AM). Other biochemical investigations
36 including a GnRH dynamic function test were unremarkable. A diagnosis of adult
37 onset TD was made and he was commenced on testosterone gel (2%) with 4
38 applications/day (each application 10mg testosterone) with haematocrit levels < 0.54
39 (0.499 – 0.536) until November 2016 (total testosterone: 6.9nmol/l (198.8ng/dl),
40 calculated free testosterone: 0.14nmol/l (4.0ng/dl)). When the testosterone gel was
41 increased to 5 daily applications in view of persisting symptoms, the haematocrit
42 increased to 0.565 (total testosterone: 12.0nmol/l (345.8ng/dl), calculated free
43 testosterone: 0.24nmol/l (6.9ng/dl)). TTh was reduced to 4 applications daily and in
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 view of increasing fatigue levels the patient was referred to the Urology clinic in
4
5 January 2017 and testosterone undecanoate injections were commenced in March
6
7 2017. Energy levels improved with this therapy and in June 2017 total testosterone
8
9 was 13.3nmol/l (383.3ng/dl), calculated free testosterone was 0.25nmol/l (7.2ng/dl)
10
11 and haematocrit was 0.536. The haematocrit had significantly increased at review in
12
13 December 2017; thus, six weeks after testosterone undecanoate administration, total
14
15 testosterone: 28.8nmol/l (830.0ng/dl), calculated free testosterone 0.70nmol/l
16
17 (20.2ng/dl) and haematocrit 0.638. The testosterone undecanoate was immediately
18
19 discontinued and the patient commenced on aspirin. A check after 3 weeks showed
20
21 the haematocrit was 0.648, serum total testosterone was 26.8nmol/l (772.3ng/dl) and
22
23 calculated free testosterone was 0.65nmol/l (18.7ng/dl). The patient underwent
24
25 immediate venesection and the haematocrit gradually reduced; January 2018: 0.557,
26
27 February 2018: 0.544, April 2018: 0.537, July 2018: 0.530. In August 2018 the
28
29 haematocrit was 0.499 with total testosterone of 3.7nmol/l (106.6ng/dl) and
30
31 calculated free testosterone of 0.08nmol/l (2.3ng/dl). The patient was suffering
32
33 severe fatigue and erectile dysfunction and wished to restart testosterone gel. At the
34
35 last follow-up in August 2018 (on 4 gel applications) the haematocrit was 0.507, total
36
37 testosterone 15.4nmol/l (443.8ng/dl) and calculated free testosterone 0.41nmol/l
38
39 (11.8ng/dl) with some clinical improvement.
40
41
42
43
44
45
46
47

48 The patient's written consent allowing us to describe this case was obtained and filed
49
50 in his hospital notes. It emphasises the need for monitoring and appropriate action
51
52 where needed. As recommended by guidelines, we used a haematocrit of 0.54 as
53
54 threshold for reducing or stopping TTh [4]. This level appears based on the
55
56 haematocrit reference range and not on evidence. Clearly, given data linking
57
58 elevated haematocrit levels with increased morbidity/mortality, an evidence-based
59
60

1
2
3 threshold value that can be used in clinical practice is needed. A further issue in
4 using TTh may be the testosterone preparation and its mode of delivery [28]. A
5 recent comprehensive review suggested short-acting, injectable testosterone is
6 associated with greater risk of elevated haematocrit compared with other
7 preparations [28]. This raises the possibility that the rate of change in serum
8 testosterone concentration may be mechanistically important; short-acting injectable
9 testosterone could lead to steeper rises and falls in hormone levels that in turn has
10 effects on erythrocytosis. However, as demonstrated by the above case, monitoring of
11 haematocrit is needed with all testosterone preparations including long-acting
12 injectable TTh.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Change in haematocrit after 30 weeks TTh in the BLAST study**

28
29 The BLAST randomised controlled trial (European Union Clinical Trials Register:
30 EudraCT 2008-000931-16) comprised a 30 week randomised double-blind placebo-
31 controlled multicentre study carried out during September 2008 - June 2012 to
32 assess the impact of TTh using testosterone undecanoate, a long-acting injectable
33 preparation in 199 men with T2DM (primary outcome: change in glycaemic control)
34 [29]. Baseline and final visit haematocrit data were available in 134 (placebo: 73
35 men, TTh: 61 men) of the 189 men completing the study (placebo: 103 men, TTh: 86
36 men). No significant change in haematocrit was observed in the placebo group
37 (baseline: 0.432, final visit: 0.435, p (paired t-test) = 0.22). The haematocrit
38 increased significantly in the TTh group (baseline: 0.444, final visit: 0.454, p (paired
39 t-test) = 0.01) but did not breach the 0.54 threshold in any patient during 30 weeks of
40 treatment.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 Haematocrit at baseline was only associated with diastolic blood pressure (linear
58 regression, coefficient (c): 0.11, 95% CI: 0.06 - 0.17, p < 0.001). When adjusted for
59
60

1
2
3 baseline age, total testosterone and other classifying characteristics of the MetS
4 (body mass index, triglycerides, HDL-cholesterol, HBA1c, systolic blood pressure),
5 this association remained significant (multiple regression, c: 0.07, 95% CI: 0.006 -
6 0.14, p = 0.03). Only baseline haematocrit (not age, total / free testosterone level or
7 metabolic parameters) was associated with the 0.010 increase in haematocrit in men
8 on TTh (c: - 0.35, 95% CI: - 0.56 - - 0.14, p = 0.001). The finding that the coefficient
9 had a negative value indicates reassuringly, that lower not higher baseline
10 haematocrit levels were associated with the largest increases. No such association
11 was observed in the placebo group (c: -0.11, 95% CI: -0.29 – 0.07, p=0.22). Figure 1
12 illustrates the change in haematocrit following 30 weeks of treatment with placebo or
13 TTh. The negative coefficient observed between baseline and change in haematocrit
14 in the BLAST patients differs from data reported by Ip et al who showed higher
15 trough testosterone levels predicted an increased haematocrit > 0.50 [30].
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 The mechanism for increased haematocrit following TTh is unclear. Coviello et al
35 demonstrated a linear dose-dependent increase in haemoglobin and haematocrit
36 levels following TTh, this observed in both 60 men aged 60 – 75 years and 61 men
37 aged 19 – 35 years. However, the increase was more evident in the older men [31].
38 Interestingly, we observed greater reductions in mortality following TTh in older men
39 [11,12]. No increase in erythropoietin or the marker of bone marrow erythropoetic
40 activity, soluble transferrin receptor, was noted. They speculated androgens may
41 have a direct stimulatory effect on the bone marrow and perhaps promote
42 differentiation of erythroid colony forming units into erythropoietin sensitive cells. In
43 contrast Bachman et al found that an increase in haemoglobin and haematocrit was
44 associated with elevated erythropoietin levels 1-3 months following TTh, but the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 levels returned to normal after 6 months [32]. Despite increased haemoglobin and
4
5 haematocrit, erythropoietin levels were not suppressed.
6
7

8 **Elevated haematocrit and increased morbidity / mortality**

9
10 We now consider longitudinal observational studies that evaluate the association
11
12 between haematocrit and CVD. While no consensus has been reached, there are
13
14 hints of a non-linear relationship. In a meta-analysis of 16 population-based
15
16 prospective studies comprising 8020 individuals (mean haematocrit = 0.440),
17
18 Danesh et al showed the top tertile of haematocrit (haematocrit >0.463) was
19
20 associated with increased coronary heart disease (risk ratio: 1.16, 95% CI: 1.05–
21
22 1.29) compared to the bottom tertile (haematocrit < 0.417) [33]. Addition of another 3
23
24 trials comprising individuals with established cardiovascular disease strengthened
25
26 the above association between the 2 extreme tertiles (risk ratio: 1.81, 95% CI: 1.19 –
27
28 2.76). However, the authors urged caution as adjustment for other coronary heart
29
30 disease risk factors which were associated with haematocrit levels, varied between
31
32 the trials.
33
34
35
36
37

38 These findings were not confirmed by the European Prospective Investigation into
39
40 Cancer and Nutrition - Netherlands (EPIC-NL) study (derived from the MORGEN-
41
42 EPIC and Prospect-EPIC studies) comprising 16,187 individuals without CVD at
43
44 baseline [34]. No association was found between the haematocrit tertiles (cut-off
45
46 values 0.45 and 0.47) and 10 year risk of CVD, strokes and coronary heart disease.
47
48 The Scottish Heart Health Extended Cohort Study estimated the predictive value of
49
50 plasma viscosity, haematocrit and whole blood viscosity (dependent on plasma
51
52 viscosity and haematocrit) for cardiovascular events in 3386 men and women aged
53
54 30 – 74 years followed up for 10 – 21 years [35]. High plasma viscosity was
55
56 independently associated with CVD events and mortality. Although haematocrit
57
58
59
60

1
2
3 (mean \pm SD: 0.4381 \pm 0.0394) was significantly associated with CVD events (HR:
4 1.14, 95% CI: 1.04 – 1.25, $p=0.004$) and mortality (HR: 1.22, 95% CI: 1.11 – 1.33,
5 $p<0.001$) when adjusted only for age and gender, significance was lost when
6 confounders such as lipids, blood pressure, diabetes, smoking status, family history
7 of CVD and fibrinogen were included.
8
9

10
11
12
13
14
15
16 A 34 year follow-up of 5209 men and women from the Framingham cohort indicated
17 that the highest haematocrit quintile was associated with increased CVD and all-
18 cause mortality [36]. A dual effect was hinted at with a J or U shaped relationship
19 between haematocrit and cardiovascular events. Further evidence for a non-linear
20 association was added by Boffetta et al; in a study of 49,983 Iranian adults, a U-
21 shaped relationship between categories of haematocrit and mortality was found in
22 both sexes, with both low and high values associated with increased overall mortality
23 [37]. In males, compared to the reference group (haematocrit 0.40–0.44), all-cause
24 mortality and mortality related to CVD were increased when the haematocrit was
25 either below 0.39 or above 0.45 (adjusted Cox regression), whilst in females
26 compared to the reference group (0.35–0.40), all-cause mortality was greater when
27 haematocrit was below 0.35 or above 0.40 and mortality related to CVD greater
28 when haematocrit was below 0.30 or above 0.40.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48
49
50 Locatelli et al studied the effects of erythropoietin in 5302 patients with end stage
51 renal disease (mean baseline haematocrit \pm SD: 0.301 \pm 0.045) on the Lombardy
52 Registry [38]. It was evident that all-cause mortality risk was inversely proportional to
53 the increase in haematocrit (OR: 0.95, 95% CI: 0.92 – 0.97) following erythropoietin
54 therapy. It was concluded that a higher haematocrit achieved either spontaneously
55 or following erythropoietin therapy improved outcomes in patients undergoing
56
57
58
59
60

1
2
3 dialysis. The findings in patients with low baseline haematocrit may be compatible
4
5 with speculation that the association between haematocrit and morbidity/mortality is
6
7 non-linear, perhaps J or U shaped. However, cautious interpretation is needed as
8
9 end stage renal disease patients are not at low mortality risk.
10
11
12
13

14 **Association between elevated haematocrit and T2DM**

15
16 A further factor potentially linking haematocrit with mortality is its association with
17
18 insulin resistance and impaired insulin secretion. This is important as adult onset TD
19
20 is associated with T2DM with greater use of TTh in these patients and risk of further
21
22 increased haematocrit levels. It is therefore, perhaps reasonable to consider T2DM
23
24 patients as a subgroup when studying the clinical consequence of elevated
25
26 haematocrit. Facchini et al. reported that increases in haematocrit and haemoglobin
27
28 levels are associated with increased insulin resistance (by measuring steady-state
29
30 plasma glucose levels after a 180-minute infusion of somatostatin, insulin and
31
32 glucose), compensatory hyperinsulinaemia, elevated blood pressure, triglycerides
33
34 and lower high density lipoprotein cholesterol values in 150 individuals [39]. When
35
36 adjusted for all the above factors in a multiple regression analysis only insulin
37
38 resistance and plasma insulin response to oral glucose remained associated with
39
40 haematocrit and haemoglobin levels. In a prospective study of 7193 middle-aged
41
42 men, Wannamethee et al. found an independent association between haematocrit
43
44 and development of T2DM, independent of age, body mass index, smoking, physical
45
46 activity, high density lipoprotein cholesterol, and systolic blood pressure [40]. T2DM
47
48 was significantly higher in men with haematocrit levels ≥ 0.48 compared with levels
49
50 <0.42 (RR: 4.5; 95% CI: 2.5-6.3, adjusted for age and body mass index). Even after
51
52 further adjustment for predictors of T2DM with which hematocrit is correlated, there
53
54
55
56
57
58
59
60

1
2
3 remained a linear association with the risk of T2DM. The authors recommended that
4 hematocrit, which is a major determinant of whole blood viscosity, should be added
5 to the cluster of risk factors that link T2DM with CVD. As previously stated in the
6 BLAST randomised controlled study HbA1c levels were not associated with baseline
7 haematocrit levels.
8
9
10
11
12
13

14
15
16
17 Clearly, monitoring haematocrit levels in men on TTh is essential [4]. An haematocrit
18 level of 0.54 has been accepted as the level at which down-titration / discontinuation
19 of TTh is recommended. Although studies hint at an association between
20 haematocrit, CVD and all-cause mortality there is no consensus view.
21
22
23
24
25
26

27 It is reasonable to speculate that increased haematocrit levels result in altered blood
28 flow characteristics that may lead to increased morbidity/mortality. Thus, it would be
29 useful to characterise the blood flow changes that occur at different haematocrit
30 levels in arteries varying in diameter. It is important that heterogeneity of disease
31 pathogenesis is recognised since the adverse effects of TTh may only be seen in
32 certain patient subgroups (Figure 2) [25]. Subgroups may be identified by broad
33 phenotypes including age, diabetes and previous CVD as well as by those specific to
34 adult onset TD and TTh; baseline testosterone and haematocrit, sexual health
35 symptoms and other clinical consequences of hypotestosteronaemia. Subgroups
36 may also be based on the extent of response to TTh or use of concomitant
37 treatments such as antihypertensives, statins and phosphodiesterase 5-inhibitors. In
38 this way the **appropriateness** of using a haematocrit level of 0.54 as the sole cut-off
39 for clinical intervention can be assessed.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

59 **Effects of haematocrit on blood flow characteristics**

60

1
2
3 A change in haematocrit is likely to affect blood flow due to increased viscosity
4 leading to altered endothelial function and perfusion. This may, in part, explain the
5 negative outcomes reported in some studies of TTh. We now focus on some
6 theoretical considerations of the effects of haematocrit on blood flow. Blood viscosity
7 is a key factor determining blood flow. Blood is a multi-component fluid comprising
8 cellular elements (platelets, leucocytes, erythrocytes) and plasma. Blood behaves as
9 a non-Newtonian fluid exhibiting shear-thinning behaviour as well as being
10 viscoelastic and thixotropic [41]. While plasma alone was considered a Newtonian
11 fluid for decades, more recent studies have shown that blood plasma has a
12 noticeable viscoelastic behaviour [42, 43]. Erythrocytes, which are deformable,
13 constitute the majority of the suspended elements in blood and have a propensity to
14 aggregate at low shear rates, forming rouleaux.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 As with most particle suspensions the viscosity of whole blood depends primarily on
34 haematocrit, erythrocyte aggregation and deformability [44]. Blood viscosity is
35 reported to increase exponentially [45] or quadratically [46] with haematocrit with the
36 effect of haematocrit being more pronounced at lower shear rates due to its effect on
37 erythrocyte aggregation contributing further to the shear thinning behaviour [47]. Wall
38 shear is known to be associated with activating endothelial function. Piety et al found
39 that increasing the haematocrit of erythrocyte suspensions in plasma *in vitro* from
40 20-60% resulted in a 3.5 fold increase in viscosity at a shear rate of 129 s⁻¹ and a
41 17.5 fold increase at 0.3 s⁻¹ [48]. Empirical correlations and various concentration
42 dependent models have been developed to describe this effect of haematocrit on
43 blood viscosity [46,49, 50]. These will allow for improved of calculated wall shear
44 stress in both micro and macrocirculation.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 It is well established that the vascular bed affects haematocrit distribution with
7
8 haematocrit levels being lower in the microvasculature. When blood flows from a
9
10 large vessel to a small-diameter one (less than about 0.3 mm), the observed
11
12 hematocrit level decrease is known as the Fåhræus effect [51]. The complex
13
14 bifurcating microvascular architecture in conjunction with the particulate nature of
15
16 blood gives rise to phenomena such as erythrocyte migration away from the wall and
17
18 plasma skimming, resulting in higher flow rate branches receiving more cells and
19
20 blood with a higher haematocrit [52]. This results in highly heterogeneous
21
22 haematocrit distributions in the microcirculation that cause local variations in
23
24 viscosity and flow resistance. This has been demonstrated in vivo [53] and in recent
25
26 microfluidic studies of blood flow [54, 55].
27
28
29
30
31
32

33 In addition to the Fåhræus effect the particulate nature of blood is also responsible
34
35 for phenomena such as leucocyte and platelet margination [56] where these smaller
36
37 cells are observed to migrate towards the vessel wall. Increased haematocrit could
38
39 lead to more interactions between erythrocytes and leucocytes or platelets promoting
40
41 margination. Interestingly, Walton et al recently showed that elevated haematocrit in
42
43 mice promoted arterial thrombosis perhaps due to rapid platelet accumulation within
44
45 the thrombus [57].
46
47
48
49
50

51 Ageing and importantly T2DM in the context of TTh, can impair blood fluidity, altering
52
53 tissue perfusion perhaps leading to functional deteriorations. It is well established
54
55 that blood fluidity becomes impaired with age and erythrocyte life span [58, 59].
56
57
58
59
60

1
2
3 Disorders such as sickle cell disease [60-62] and diabetes [63-67] have been
4
5 associated with reduced erythrocyte deformability.
6
7

8
9
10 Lower deformability of erythrocytes in T2DM has been associated with poor
11
12 glycaemic control and microvascular complications such as diabetic retinopathy [68].
13
14 Erythrocytes in individuals with T2DM also undergo morphological changes with their
15
16 shape deviating from the established biconcave disc to a more elongated shape [69].
17
18 These changes together with enhanced erythrocyte aggregation in T2DM can result
19
20 in elevated blood viscosity which may be a factor in the pathogenesis of
21
22 microvascular disease and non-flow limiting coronary artery disease [70, 71]. It is
23
24 possible this risk is exacerbated by TTh associated increase in haematocrit.
25
26
27
28
29

30
31 Changes in macrovascular flow characteristics that may be associated with
32
33 increased haematocrit are also potentially important. Both end diastolic and peak
34
35 systolic velocities have been associated with atherogenesis [72-76]. Our research
36
37 group found that lower peak systolic velocity, based on ultrasound measurements in
38
39 the carotid artery, was associated with coronary heart disease [72].
40
41
42
43
44

45 **Optimal haematocrit**

46
47 Salazar-Vazquez et al [77] suggested that the treatment of diabetes should target
48
49 the maintenance of an optimal haematocrit in order to lower cardiovascular risk,
50
51 prompting the question what is the ideal haematocrit? Clinical guidelines use a value
52
53 <0.54 based on a population distribution and not physiological evaluation. Increased
54
55 haematocrit should theoretically increase tissue oxygenation as oxygen content
56
57 varies linearly with haematocrit. However, it also increases blood viscosity in an
58
59
60

1
2
3 exponential function reducing blood flow; hence an ideal haematocrit should exist
4 that optimises tissue oxygenation and flow performance. A recent *in vitro* study
5 concluded that the optimum haematocrit is different for large and small vessels,
6 attributed to the difference in driving pressures and hence perfusion rates [48]. Many
7 cardiovascular conditions result in lower blood flow rates either in systemic
8 circulation or locally which might result in the optimal haematocrit being lower than
9 the physiological one. This could be due to rheological changes brought about by
10 impaired erythrocyte deformability or increased erythrocyte aggregation, endothelial
11 dysfunction or decreased cardiac output [45]. An increase in haematocrit will
12 increase whole blood viscosity which in turn will require a high blood pressure to
13 maintain flow. Whilst the required increase in blood pressure can be quantified easily
14 *in vitro*, the situation is more complex *in vivo*. Factors such as altered vessel
15 elasticity, endothelial function and release of vasodilators (e.g. nitric oxide) may
16 influence the compensatory mechanisms. The above makes a case for individuals
17 with T2DM to be considered as a subgroup since the efficiency of these factors may
18 differ from that in health. In sickle cell anaemia, for example, the optimum
19 haematocrit for transfusion has been set below 0.30 [78]. This implies that the
20 optimum haematocrit in disease is subgroup specific and depends on the many
21 factors impacting blood rheology.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Therapeutic phlebotomy is the mainstay of controlling haematocrit in polycythaemia
50 vera (PV). Some experts suggest haematocrit targets of < 0.45 in men and < 0.42
51 percent in women [79-82]. A prospective trial randomly assigned 365 adults with PV
52 to more intensive treatment (target haematocrit, < 0.45) versus less intensive
53 treatment (target haematocrit: 0.45 – 0.50 percent); control of haematocrit achieved
54
55
56
57
58
59
60

1
2
3 by phlebotomy, hydroxyurea, or both. After a median follow-up of 31 months,
4
5 compared with the more intensive therapy group, the less intensive therapy was
6
7 associated with shorter time to death from CVD or major thrombotic events (HR: 3.9,
8
9 95% CI: 1.5-10.5]; with events reported in 10% of the less intensive therapy group
10
11 and 3 % in the more intensive treatment group [80].
12
13
14
15
16
17
18

19 **Conclusion**

20
21 Although TTh use has increased with most studies demonstrating benefit, doubts of
22
23 its safety based on a few controversial reports of increased CVD remain. We have
24
25 seen that increased haematocrit is the commonest adverse effect of TTh and
26
27 guidelines regarding action thresholds are based on a population derived level of
28
29 0.54. Longitudinal studies suggest that haematocrit influences CVD morbidity and
30
31 mortality, although the association may not be linear. It is clear that further studies
32
33 are required and we propose that in addition to clinical studies with hard and
34
35 surrogate end-points, changes in blood flow characteristics should be evaluated
36
37 across macro- and micro-circulatory vascular beds.
38
39
40
41
42
43
44

45 Advanced computational tools are required to understand the particulate nature of
46
47 blood in the microcirculation taking into account the impact of increased haematocrit
48
49 and altered erythrocyte properties. Although this has been carried out in some
50
51 pathologies (sickle cell anaemia [83], malaria [84]) only simple vascular geometries
52
53 rather than networks were considered. Microfluidics has allowed microscale blood
54
55 flow characteristics to be probed allowing cell and flow distribution to be resolved
56
57 and phenomena such as erythrocyte aggregation and deformability on those to be
58
59
60

1
2
3 studied in detail [52, 53]. Thus, concurrent studies of clinical outcomes and
4
5 evaluation of flow changes following haematocrit change during TTh in different
6
7 patient groups will allow management guidance based on evidence that allows for
8
9 patient heterogeneity.
10
11
12

13 14 **References**

- 15 1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal
16 effects of aging on serum total and free testosterone levels in healthy men.
17 Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab* 2001; 86:
18 724–731.
19
- 20 2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE,
21 et al. Prevalence of symptomatic androgen deficiency in men. *J Clin*
22 *Endocrinol Metab* 2007; 92: 4241–4247.
23
- 24 3. Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A.
25 Serum testosterone levels in male hypogonadism: Why and when to check —
26 A review. *Int J Clin Pract.* 2017; 71:e12995.
27
28
- 29 4. Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N et al.
30 British Society for Sexual Medicine guidelines on adult testosterone
31 deficiency, with statements for UK practice. *J Sex Med* 2017; 14: 1504-1523.
32
33
- 34 5. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and
35 biochemical assessment of hypogonadism in men with type 2 diabetes:
36 correlations with bioavailable testosterone and visceral adiposity. *Diabetes*
37 *Care* 2007; 30: 911–917.
38
39
- 40 6. Hackett G, Cole N, Deshpande A, Popple M, Kennedy D, Wilkinson P.
41 Biochemical hypogonadism and type 2 diabetes in primary care. *The British*
42 *Journal of Diabetes & Vascular Disease* 2009; 9: 226–231.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 7. Holmboe SA, Jensen TK, Linneberg A, Scheike T, Thuesen BH, Skakkebaek
4
5 NE et al. Low Testosterone: A Risk Marker Rather Than a Risk Factor for
6
7 Type 2 Diabetes. *J Clin Endocrinol Metab* 2016; 101: 3180–3190.
8
9
- 10 8. Pye SR, Huhtaniemi JD, Finn DM, Lee TW, O'Neill AT, Tajar A et al. Late-
11
12 onset hypogonadism and mortality in aging men. *J Clin Endocrinol Metab*
13
14 2014; 99: 1357–1366.
15
16
- 17 9. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM.
18
19 Testosterone treatment and mortality in men with low testosterone levels. *J*
20
21 *Clin Endocrinol Metab* 2012; 97: 2050–2058.
22
23
- 24 10. Muraleedaran V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone
25
26 deficiency is associated with increased risk of mortality and testosterone
27
28 replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol*
29
30 2013; 169: 725–733.
31
32
- 33 11. Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S.
34
35 Serum testosterone, testosterone replacement therapy and all-cause mortality
36
37 in men with type 2 diabetes: retrospective consideration of the impact of
38
39 PDE5 inhibitors and statins. *Int J Clin Pract* 2016; 70: 244–253.
40
41
42
43
- 44 12. Hackett G, Jones PW, Strange RC, Ramachandran S. Statin, testosterone
45
46 and phosphodiesterase 5-inhibitor treatments and age related mortality in
47
48 diabetes. *World J Diabetes* 2017; 8: 104–111.
49
50
- 51 13. Hackett GI, Cole N, Mulay A, Strange RC, Ramachandran S. Long-term
52
53 Testosterone Therapy in Type 2 Diabetes is associated with reduced Mortality
54
55 without improvement in conventional cardiovascular risk factors. *BJU Int* 2018
56
57 (in press: Epub ahead of print;
58
59 <https://www.ncbi.nlm.nih.gov/pubmed/?term=Long->
60

1
2
3 term+Testosterone+Therapy+in+Type+2+Diabetes+is+associated+with+redu
4
5 ced+Mortality+without+improvement+in+conventional+cardiovascular+risk+fa
6
7 ctors – accessed 02/01/2019)

- 10 14. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields
11
12 AJ, Cauley JA et al. Effects of testosterone treatment in older men. *N Engl J*
13
14 *Med* 2016; 374: 611–624.
- 15
16
17 15. Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
18
19 Testosterone Undecanoate improves sexual function in men with type 2
20
21 diabetes and severe Hypogonadism: results from a 30 week randomised
22
23 placebo controlled study. *BJU Int* 2016; 118: 804-813.
- 24
25
26 16. Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
27
28 Testosterone replacement therapy: improved sexual desire and erectile
29
30 function in men with type 2 diabetes following a 30-week randomized placebo-
31
32 controlled study. *Andrology* 2017; 5: 905-913.
- 33
34
35 17. Hackett GI, Cole N, Mulay A, Strange RC, Ramachandran S. Long term
36
37 testosterone therapy in type 2 diabetes is associated with decreasing waist
38
39 circumference and improving erectile dysfunction. *World J Mens Health* 2018
40
41 (in press: Epub ahead of print;
42
43 [https://www.ncbi.nlm.nih.gov/pubmed/?term=Long+term+testosterone+therap
44
45 y+in+type+2+diabetes+is+associated+with+decreasing+waist+circumference
46
47 +and+improving+erectile+dysfunction](https://www.ncbi.nlm.nih.gov/pubmed/?term=Long+term+testosterone+therapy+in+type+2+diabetes+is+associated+with+decreasing+waist+circumference+and+improving+erectile+dysfunction) – accessed 02/01/2019).
- 48
49
50
51 18. Miner M, Morgentaler A, Kheira M, Traish AM. The state of testosterone
52
53 therapy since the FDA's 2015 labelling changes: indications and
54
55 cardiovascular risk. *Clin Endocrinol (Oxf)* 2018; 89: 3-10.
56
57
58
59
60

- 1
2
3 19. Morgentaler A, Zitzmann M, Traish AM, Fox AW, Hugh Jones T, Maggi M et
4
5 al. Fundamental Concepts Regarding Testosterone Deficiency and
6
7 Treatment: International Expert Consensus Resolutions. *Mayo Clin Proc.*
8
9 2016; 91:881-896.
10
11
- 12 20. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM et
13
14 al. Association of testosterone therapy with mortality, myocardial infarction,
15
16 and stroke in men with low testosterone levels. *JAMA* 2013; 310: 1829–1836.
17
18
- 19 21. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB et
20
21 al. Increased risk of non-fatal myocardial infarction following testosterone
22
23 therapy prescription in men. *PLoS One* 2014; 9: e85805.
24
25
- 26 22. Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M,
27
28 Holtzmann M J. Association between treatment for erectile dysfunction and
29
30 death or cardiovascular outcomes after myocardial infarction. *Heart* 2017;
31
32 103: 1264-1270.
33
34
- 35 23. Anderson SG, Hutchings DC, Woodward M, Rahimi K, Rutter MK, Kirby M et
36
37 al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated
38
39 with a reduction in all-cause mortality. *Heart* 2016; 102: 1750-1756.
40
41
- 42 24. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM et al.
43
44 Adverse events associated with testosterone administration. *N Engl J Med*
45
46 2010; 363: 109-122.
47
48
- 49 25. Ramachandran S, König CS, Hackett G, Livingston M, Strange RC. Managing
50
51 clinical heterogeneity: An argument for benefit based action limits. *Journal of*
52
53 *Medical Diagnostics and Therapy* 2018; 1: 034701.
54
55
- 56 26. Calof O, Singh AB, Lee ML, Urban RJ, Kenny AM, Tenover JL et al. Adverse
57
58 events associated with testosterone supplementation of older men: a meta-
59
60

- 1
2
3 analysis of randomized, placebo-controlled trials. *J Gerontol A Med Sci* 2005;
4 60:1451–1457.
5
6
7
8 27. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff
9 RS et al. Testosterone therapy in men with androgen deficiency syndromes:
10 an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*.
11 2010; 95: 2536–2559.
12
13
14
15
16
17 28. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following
18 Testosterone Therapy. *Sex Med Rev* 2018; 6: 77-85.
19
20
21
22 29. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, and Wilkinson P.
23 Testosterone replacement therapy with long-acting Testosterone
24 Undecanoate improves sexual function and quality-of-life parameters vs.
25 placebo in a population of men with type 2 diabetes. *J Sex Med* 2013; 10:
26 1612–1627.
27
28
29
30
31
32
33 30. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough
34 serum testosterone predicts the development of polycythemia in hypogonadal
35 men treated for up to 21 years with subcutaneous testosterone pellets. *Eur J*
36 *Endocrinol* 2010; 162: 385-390.
37
38
39
40
41
42 31. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects
43 of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and
44 Older Men. *J Clin Endocrinol Metab* 2008; 93: 914 –919.
45
46
47
48
49 32. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M et al.
50 Testosterone induces erythrocytosis via increased erythropoietin and
51 suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point.
52 *J Gerontol A Biol Sci Med Sci* 2014; 69: 725-735.
53
54
55
56
57
58
59
60

- 1
2
3 33. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erythrocyte
4 sedimentation rate: meta-analyses of prospective studies of coronary heart
5 disease. *Eur Heart J* 2000; 21: 515–520.
6
7
8
9
10 34. Lassale C, Curtis A, Abete I, van der Schouw YT, Verschuren WMM, Lu Y et
11 al. Elements of the complete blood count associated with cardiovascular
12 disease incidence: Findings from the EPIC-NL cohort study. *Sci Rep.* 2018;
13 8:3290.
14
15
16
17
18
19 35. Peters SA, Woodward M, Rumley A, Tunstall-Pedoe HD, Lowe GD. Plasma
20 and blood viscosity in the prediction of cardiovascular disease and mortality in
21 the Scottish Heart Health Extended Cohort Study. *Eur J Prev Cardiol* 2016;
22 24: 161-167.
23
24
25
26
27
28 36. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and
29 the risk of cardiovascular disease--the Framingham study: a 34-year follow-
30 up. *Am Heart J* 1994; 127: 674-682.
31
32
33
34
35 37. Boffetta P, Islami F, Vedanthan R, Pourshams A, Kamangar F, Khademi H et
36 al. A U-shaped relationship between haematocrit and mortality in a large
37 prospective cohort study. *Int J Epidemiol* 2013; 42: 601–615.
38
39
40
41
42 38. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and
43 erythropoietin treatment on overall and cardiovascular mortality and morbidity-
44 the experience of the Lombardy Dialysis Registry. *Nephrol Dial Transplant.*
45 1998; 13: 1642-1644.
46
47
48
49
50
51 39. Facchini FS, Carantoni M, Jeppesen J, Reaven GM. Hematocrit and
52 hemoglobin are independently related to insulin resistance and compensatory
53 hyperinsulinemia in healthy, non-obese men and women. *Metabolism* 1998;
54 47: 831-835.
55
56
57
58
59
60

- 1
2
3 40. Wannamethee SG, Perry IJ, Shaper AG. Hematocrit and risk of NIDDM.
4
5 Diabetes 1996; 45: 576-579.
6
7
8 41. Antonova N. On some mathematical models in hemorheology. Biotechnology
9
10 & Biotechnological. Equipment 2012; 26: 3286-3291.
11
12
13 42. Varchanis S, Dimakopoulos Y, Wagnerb C, Tsamopoulosa J. How
14
15 viscoelastic is human blood plasma? Soft Matter 2018; 14: 4238-4251.
16
17 43. Brust M, Schaefer C, Doerr R, Pan L, Garcia M, Arratia PE et al.
18
19 Rheology of Human Blood Plasma: Viscoelastic Versus Newtonian Behavior.
20
21 Phys Rev Lett 2013; 110: 078305.
22
23
24 44. Pasquini G, Albanese B, Manescalchi PG, Morini R. Relation of blood
25
26 viscosity, plasma viscosity and haematocrit. Ric Clin Lab 1983; 13 Suppl 3:
27
28 327-331.
29
30
31 45. Reinhart WH. The optimum hematocrit. Clin Hemorheol Microcirc 2016; 64:
32
33 575–585.
34
35
36 46. Apostolidis AJ, Beris AN. Modeling of the blood rheology in steady-state shear
37
38 flows. J. Rheol 2014; 58: 607-633.
39
40
41 47. Sousa PC, Pinho FT, Alves MA, Oliveira MSN. A review of hemorheology:
42
43 Measuring techniques and recent advances. Korea-Australia Rheology
44
45 Journal 2016; 28:1-22.
46
47
48 48. Piety NZ, Reinhart WH, Stutz J, Shevkopyas SS. Optimal hematocrit in an
49
50 artificial microvascular network. Transfusion 2017; 57; 2257–2266.
51
52
53 49. Picart C, Piau JM, Galliard H, Carpentier P. Blood yield stress and its
54
55 Hematocrit Dependence. J Rheol 1998; 42:1-12.
56
57
58 50. Hund SJ, Kameneva MV, Antaki JF. A quasi-mechanistic mathematical
59
60 representation for blood viscosity. Fluids 2017; 2: 10.

- 1
2
3 51. Secomb TW, Pries AR. Blood viscosity in microvessels: experiment and
4
5 theory. *C R Phys* 2013; 14: 470–478.
6
7
- 8 52. Secomb TW. Blood Flow in the Microcirculation. *Annual Review of fluid*
9
10 *Mechanics* 2017; 49: 443–461.
11
- 12 53. Pries AR, Ley K, Claassen M, Gaehtgens P. 1989. Red cell distribution at
13
14 microvascular bifurcations. *Microvasc Res*; 38: 81–101.
15
16
- 17 54. Sherwood J, Holman D, Kaliviotis E, Balabani S. Spatial distributions of red
18
19 blood cells significantly alter local haemodynamics. *PLoS One* 2014; 9:
20
21 e100473.
22
- 23 55. Kaliviotis E, Sherwood JM, Balabani S. Local viscosity distribution in
24
25 bifurcating microfluidic blood flows. *Physics of Fluids* 2018; 30: 030706.
26
27
- 28 56. Chang H-Y, Yazdani A, Li X, Douglas KAA, Mantzoros CS, Karniadakis GE.
29
30 Quantifying Platelet Margination in Diabetic Blood Flow. *Biophysical Journal*
31
32 2018; 115: 1371-1382.
33
34
- 35 57. Walton BL, Lehmann M, Skorczewski T, Holle LA, Beckman JD, Cribb JA et
36
37 al. Elevated hematocrit enhances platelet accumulation following vascular
38
39 injury. *Blood* 2017; 129: 2537-2546.
40
41
- 42 58. Huang YX, Wu ZJ, Mehrishi J, Huang BT, Chen XY, Zheng XJ et al. Human
43
44 red blood cell aging: correlative changes in surface charge and cell properties.
45
46 *J Cell Mol Med* 2011; 15: 2634–2642.
47
48
- 49 59. Simmonds MJ, Meiselman HJ, Baskurt OK. Blood rheology and aging. *J*
50
51 *Geriatr Cardiol* 2013; 10: 291–301.
52
53
- 54 60. Alapan Y, Little J, Gurkan UA. Heterogeneous Red Blood Cell Adhesion and
55
56 Deformability in Sickle Cell Disease. *Sci Rep* 2014; 4: 7173.
57
58
59
60

- 1
2
3 61. Alapan Y, Matsuyama Y, Little J, Gurkan UA. Dynamic deformability of sickle
4 red blood cells in microphysiological flow. *Technology (Singap World Sci)*
5
6 2016; 4: 71–79.
7
8
9
10 62. Dufu K, Patel M, Oksenberg D, Cabrales P. GBT440 improves red blood cell
11 deformability and reduces viscosity of sickle cell blood under deoxygenated
12 conditions. *Clin Hemorheol Microcirc* 2018; 70: 95-105.
13
14
15
16 63. Vague P, Juhan I. Red cell deformability, platelet aggregation, and insulin
17 action. *Diabetes* 1983; 32 Suppl 2:88-91.
18
19
20
21 64. Sabo A, Jakovljević V, Stanulović M, Lepsanović L, Pejin D. Red blood cell
22 deformability in diabetes mellitus: effect of phytomenadione. *Int J Clin*
23
24 *Pharmacol Ther Toxicol* 1993; 31: 1-5.
25
26
27
28 65. Keymel S, Heiss C, Kleinbongard P, Kelm M, Lauer T. Impaired red blood cell
29 deformability in patients with coronary artery disease and diabetes mellitus.
30
31 *Horm Metab Res* 2011; 43: 760-765.
32
33
34
35 66. Agrawal R, Smart T, Nobre-Cardoso J, Richards C, Bhatnagar R, Tufail A et
36 al. Assessment of red blood cell deformability in type 2 diabetes mellitus and
37
38 diabetic retinopathy by dual optical tweezers stretching technique. *Sci Rep.*
39
40 2016; 6: 15873.
41
42
43
44 67. Fornal M, Lekka M, Pyka-Fościk G, Lebed K, Grodzicki T, Wizner B et al.
45 Erythrocyte stiffness in diabetes mellitus studied with atomic force microscope
46
47 *Clin Hemorheol Microcirculation* 2006; 35: 273–276.
48
49
50
51 68. Moon JS, Kim JH, Kim JH, Park IR, Lee JH, Kim HJ et al. Impaired RBC
52 deformability is associated with diabetic retinopathy in patients with type 2
53
54 diabetes. *Diabetes Metab* 2016; 42:448-452.
55
56
57
58
59
60

- 1
2
3 69. Pretorius E, Kell DB. Diagnostic morphology: biophysical indicators for iron-
4 driven inflammatory diseases. *Integr Biol (Camb)* 2014; 6: 486-510.
5
6
7
8 70. Cho YI, Mooney MP, Cho DJ. Hemorheological Disorders in Diabetes
9 Mellitus. *J Diabetes Sci Technol* 2008; 2: 1130-1138.
10
11
12 71. Lin T, Rechenmacher S, Rasool S, Varadarajan P, Pai RG. Reduced Survival
13 in Patients with “Coronary Microvascular Disease” *Int J Angiol* 2012; 21: 89–
14 94.
15
16
17
18
19 72. König CS, Atherton M, Cavazutti M, Ramachandran S, Gomm C, Strange RC
20 et al. A pilot study to assess peak systolic velocity as a possible marker of
21 atherosclerotic burden using ultrasound. *Artery Research* 2017; 20: 76.
22
23
24 73. Chuang SY, Bai CH, Cheng HM, Chen JR, Yeh WT, Hsu PF et al. Common
25 carotid artery end-diastolic velocity is independently associated with future
26 cardiovascular events. *Eur J Prev Cardiol* 2016; 23:116-124.
27
28
29 74. El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in
30 patients with erectile dysfunction. *J Urol* 2004; 172: 251-254.
31
32
33 75. Gupta N, Herati A, Gilbert BR. Penile Doppler ultrasound predicting
34 cardiovascular disease in men with erectile dysfunction. *Curr Urol Rep* 2015;
35 16: 16.
36
37
38
39 76. Westholm C, Johnson J, Sahlen A, Winter R, Jernberg T. Peak systolic
40 velocity using color-coded tissue Doppler imaging, a strong and independent
41 predictor of outcome in acute coronary syndrome patients. *Cardiovasc*
42 *ultrasound* 2013; 11: 9.
43
44
45 77. Salazar-Vasquez BY, Intaglietta M, Rodriguez-Moran M, Guerrero-Romero F.
46 Blood pressure and haematocrit in diabetes and the role of endothelial
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 responses in the variability of blood viscosity. *Diabetes Care* 2006; 29: 1523-
4
5 1528.

6
7
8 78. Wun T, Hassell K. Best practices for transfusion for patients with sickle cell
9
10 disease. *Hematol Rev* 2009; 1: e22.

11
12 79. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et
13
14 al. Philadelphia-negative classical myeloproliferative neoplasms: critical
15
16 concepts and management recommendations from European LeukemiaNet. *J*
17
18 *Clin Oncol*, 2011. 29: 761-770.

19
20
21 80. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al.
22
23 Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl*
24
25 *J Med* 2013; 368: 22-33.

26
27
28 81. Finazzi G, Barbui T. How I treat patients with polycythemia vera. *Blood* 2007;
29
30 109: 5104-5111.

31
32
33 82. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current
34
35 practice. *Semin Hematol* 2005; 42: 206-220.

36
37
38 83. Li X, Li H, Chang HY, Lykotrafitis G, Em Karniadakis G. Computational
39
40 Biomechanics of Human Red Blood Cells in Hematological Disorders. *J*
41
42 *Biomech Eng* 2017; 139: 0210081-02100813.

43
44
45 84. Fedosov DA, Pan W, Caswell B, Gompper G, Karniadakis GE. Predicting
46
47 human blood viscosity in silico. *Proc Natl Acad Sci USA* 2011; 108: 11772-
48
49 11777.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Figure 1: Change in haematocrit following 30 weeks of treatment in the placebo and TTh groups (BLAST study of men with T2DM).





Figure 2: A diagrammatic scheme of the importance of heterogeneity in complex diseases.

This figure was previously published in: Ramachandran S, König CS, Hackett G, Livingston M, Strange RC. Managing clinical heterogeneity: An argument for benefit based action limits. *Journal of Medical Diagnostics and Therapy* 2018; 1: 034701


(permission to use the figure was obtained from the journal)




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



er Review



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60